Cargando…
Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
BACKGROUND: SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity is induced upon both infection and vaccination. However, defining the long-term immune trajectory, especially after infection, is limited. In this study, we aimed to further the understanding of long-term SARS-CoV...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652616/ https://www.ncbi.nlm.nih.gov/pubmed/37974069 http://dx.doi.org/10.1186/s12865-023-00583-y |
_version_ | 1785147722721918976 |
---|---|
author | Hvidt, Astrid Korning Guo, Huaijian Andersen, Rebecca Lende, Stine Sofie Frank Vibholm, Line Khalidan Søgaard, Ole Schmeltz Schleimann, Marianne Hoegsbjerg Russell, Victoria Cheung, Angela Man-Wei Paramithiotis, Eustache Olesen, Rikke Tolstrup, Martin |
author_facet | Hvidt, Astrid Korning Guo, Huaijian Andersen, Rebecca Lende, Stine Sofie Frank Vibholm, Line Khalidan Søgaard, Ole Schmeltz Schleimann, Marianne Hoegsbjerg Russell, Victoria Cheung, Angela Man-Wei Paramithiotis, Eustache Olesen, Rikke Tolstrup, Martin |
author_sort | Hvidt, Astrid Korning |
collection | PubMed |
description | BACKGROUND: SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity is induced upon both infection and vaccination. However, defining the long-term immune trajectory, especially after infection, is limited. In this study, we aimed to further the understanding of long-term SARS-CoV-2-specific immune response after infection. RESULTS: We conducted a longitudinal cohort study among 93 SARS-CoV-2 recovered individuals. Immune responses were continuously monitored for up to 20 months after infection. The humoral responses were quantified by Spike- and Nucleocapsid-specific IgG levels. T cell responses to Spike- and non-Spike epitopes were examined using both intercellular cytokine staining (ICS) assay and Activation-Induced marker (AIM) assay with quantification of antigen-specific IFNγ production. During the 20 months follow-up period, Nucleocapsid-specific antibody levels and non-Spike-specific CD4 + and CD8 + T cell frequencies decreased in the blood. However, a majority of participants maintained a durable immune responses 20 months after infection: 59% of the participants were seropositive for Nucleocapsid-specific IgG, and more than 70% had persisting non-Spike-specific T cells. The Spike-specific response initially decreased but as participants were vaccinated against COVID-19, Spike-specific IgG levels and T cell frequencies were boosted reaching similar or higher levels compared to 1 month post-infection. The trajectory of infection-induced SARS-CoV-2-specific immunity decreases, but for the majority of participants it persists beyond 20 months. The T cell response displays a greater durability. Vaccination boosts Spike-specific immune responses to similar or higher levels as seen after primary infection. CONCLUSIONS: For most participants, the response persists 20 months after infection, and the cellular response appears to be more long-lived compared to the circulating antibody levels. Vaccination boosts the S-specific response but does not affect the non-S-specific response. Together, these findings support the understanding of immune contraction, and with studies showing the immune levels required for protection, adds to the knowledge of durability of protection against future SARS-CoV-2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12865-023-00583-y. |
format | Online Article Text |
id | pubmed-10652616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106526162023-11-16 Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study Hvidt, Astrid Korning Guo, Huaijian Andersen, Rebecca Lende, Stine Sofie Frank Vibholm, Line Khalidan Søgaard, Ole Schmeltz Schleimann, Marianne Hoegsbjerg Russell, Victoria Cheung, Angela Man-Wei Paramithiotis, Eustache Olesen, Rikke Tolstrup, Martin BMC Immunol Research BACKGROUND: SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity is induced upon both infection and vaccination. However, defining the long-term immune trajectory, especially after infection, is limited. In this study, we aimed to further the understanding of long-term SARS-CoV-2-specific immune response after infection. RESULTS: We conducted a longitudinal cohort study among 93 SARS-CoV-2 recovered individuals. Immune responses were continuously monitored for up to 20 months after infection. The humoral responses were quantified by Spike- and Nucleocapsid-specific IgG levels. T cell responses to Spike- and non-Spike epitopes were examined using both intercellular cytokine staining (ICS) assay and Activation-Induced marker (AIM) assay with quantification of antigen-specific IFNγ production. During the 20 months follow-up period, Nucleocapsid-specific antibody levels and non-Spike-specific CD4 + and CD8 + T cell frequencies decreased in the blood. However, a majority of participants maintained a durable immune responses 20 months after infection: 59% of the participants were seropositive for Nucleocapsid-specific IgG, and more than 70% had persisting non-Spike-specific T cells. The Spike-specific response initially decreased but as participants were vaccinated against COVID-19, Spike-specific IgG levels and T cell frequencies were boosted reaching similar or higher levels compared to 1 month post-infection. The trajectory of infection-induced SARS-CoV-2-specific immunity decreases, but for the majority of participants it persists beyond 20 months. The T cell response displays a greater durability. Vaccination boosts Spike-specific immune responses to similar or higher levels as seen after primary infection. CONCLUSIONS: For most participants, the response persists 20 months after infection, and the cellular response appears to be more long-lived compared to the circulating antibody levels. Vaccination boosts the S-specific response but does not affect the non-S-specific response. Together, these findings support the understanding of immune contraction, and with studies showing the immune levels required for protection, adds to the knowledge of durability of protection against future SARS-CoV-2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12865-023-00583-y. BioMed Central 2023-11-16 /pmc/articles/PMC10652616/ /pubmed/37974069 http://dx.doi.org/10.1186/s12865-023-00583-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hvidt, Astrid Korning Guo, Huaijian Andersen, Rebecca Lende, Stine Sofie Frank Vibholm, Line Khalidan Søgaard, Ole Schmeltz Schleimann, Marianne Hoegsbjerg Russell, Victoria Cheung, Angela Man-Wei Paramithiotis, Eustache Olesen, Rikke Tolstrup, Martin Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study |
title | Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study |
title_full | Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study |
title_fullStr | Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study |
title_full_unstemmed | Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study |
title_short | Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study |
title_sort | long-term humoral and cellular immunity after primary sars-cov-2 infection: a 20-month longitudinal study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652616/ https://www.ncbi.nlm.nih.gov/pubmed/37974069 http://dx.doi.org/10.1186/s12865-023-00583-y |
work_keys_str_mv | AT hvidtastridkorning longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT guohuaijian longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT andersenrebecca longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT lendestinesofiefrank longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT vibholmlinekhalidan longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT søgaardoleschmeltz longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT schleimannmariannehoegsbjerg longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT russellvictoria longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT cheungangelamanwei longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT paramithiotiseustache longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT olesenrikke longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy AT tolstrupmartin longtermhumoralandcellularimmunityafterprimarysarscov2infectiona20monthlongitudinalstudy |